Fast Five Quiz: Migraine Complications and Comorbidities
What do you know about the complications and comorbidities of migraine? Check your knowledge with this quiz.
Ischemic stroke is a complication among patients with migraine, especially among those who experience aura. Although the prevalence of stroke in migraine is relatively low, a recent review found that migraine with aura is consistently associated with higher risk for various cardiovascular complications than migraine without aura, with the evidence being the strongest for ischemic stroke. Lifestyle factors such as smoking and oral contraceptive use have also been found to increase the risk for stroke in patients with migraine.
Unilateral frontotemporal pain can be a typical symptom of migraine that is not as strongly associated with ischemic stroke, especially if it is not accompanied by aura; nausea and/or vomiting and mood changes are not strongly associated with ischemic stroke in patients with migraine as well.
Learn more about migraine symptoms.
Depression and migraine are found to have a bidirectional association, as well as shared genetic factors. Further, depression can be linked to any severity of migraine; patients who are treated for migraine can still experience depression as well. The dysregulation of the hypothalamic and thalamic pathways has been implicated as a possible cause in both diseases.
Learn more about depression in migraine.
Migrainous infarction is a rare complication that is defined as ischemic infarction in relevant areas occurring in a patient experiencing migraine with aura for over 60 minutes, which can be accounted for by no other International Classification of Headache Disorders (ICHD) diagnosis. Data indicate that migrainous infarction is implicated in up to 1.5% of all ischemic stroke cases and typically occurs in younger (29-39 years) patients. However, when compared with "strokes from traditional risk factors," researchers claim the prognosis for migrainous infarction is generally favorable.
Learn more about infarction in migraine.
Epilepsy is common in hemiplegic migraine, with one review citing occurrence in approximately 40% of patients with this migraine subtype. It also has a strong genetic component that it shares with epilepsy; several mutations, such as in the CACNA1A, ATP1A2, SCN1A, and PRRT2 genes, are seen in both diseases. As such, there is overlap in symptom presentation and even triggering mechanisms for both migraine and epilepsy, and the electrical signature of both diseases in the brain is similar.
Migraine without aura and retinal migraine can cause seizures in some patients, but they are not strongly associated with epilepsy. Migraine with aura is also a known seizure trigger, although not exclusively for epilepsy.
Learn more about migraine symptoms and presentation.
Sleep disorders such as insomnia, narcolepsy, restless leg syndrome, and obstructive sleep apnea are also associated with migraine, and sleep deprivation is known to be a migraine trigger as well. Data indicate that sleep complaints are more prevalent in patients with chronic migraine, which is consistent with a recent survey finding that headache frequency, but not severity, was associated with insomnia. As headache frequency increases and migraine proceeds to chronification, clinicians should be aware of the potential for further sleep-related quality of life deficits.
Learn more about migraine symptoms and presentation.
Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Centene raises Wall Street optimism that Medicaid insurers can improve profits
By Amina Niasse NEW YORK (Reuters) -Wall Street regained confidence in Medicaid insurers after Centene said on Friday it expects to be able to raise rates charged to states for 2026 health plans for low-income Americans and strengthen profit margins. Insurer shares rose across the board. Centene shares were up 5% in early afternoon trading after falling 16% on the company's announcement of a second-quarter loss and forecast cut. Rivals UnitedHealth, CVS Health and Humana rose 1.61%, 2.69% and 3.45%, respectively. All three report earnings next week. Centene in an earnings call reassured investors it would work with states to ensure their payments for Medicaid plans match the company's increased medical costs for 2026. 'Our goal is to reprice 100%' of plans, said company CEO Sarah London. Insurers are paid a set amount by states for Medicaid plans, which are jointly funded with the federal government. Centene, UnitedHealth and Elevance have said this year that state reimbursements for these plans have lagged behind actual costs of care. Cautious investors have been looking for Medicaid health plan design changes and strategic geographic changes by the companies to reduce use of healthcare services. New work requirements for Medicaid recipients in President Donald Trump's signature tax-cut and spending bill have made some investors worry that healthy people could disenroll in coming years. The bill requires states to verify certain members are working or volunteering a minimum of 80 hours per month to qualify for Medicaid coverage starting in 2027. After a COVID-19 era requirement to keep people enrolled expired in 2023, Medicaid plans redetermined each person's eligibility. This pushed members off, changing the mix of sick and healthy participants, and some Medicaid insurers struggled. 'The Medicaid redeterminations have proven to be far more disruptive than anyone thought," said Jeff Jonas, a portfolio manager at Gabelli Funds. "The entire industry is focused on restoring margin over winning new contracts and membership." More detailed data could justify midyear price increases, said Kevin Gade, chief operating officer at Bahl & Gaynor, and correct mismatched rates set by states after the pandemic. More data over the next year will also enable insurers to improve cost management techniques and raise rates paid by states, Gade said. "With enough data you can take care of the problem.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
4 minutes ago
- Fox News
Otters beat the heat with frozen fish treats at Memphis Zoo
At the Memphis Zoo, otters beat the Tennessee heat with frozen fish treats that are part snack, part cooling enrichment.
Forbes
4 minutes ago
- Forbes
The Prototype: Bringing Advanced Semiconductor Manufacturing Back To The U.S.
In this week's edition of The Prototype, we look at a federal program to bring advanced semiconductor R&D to Florida, a quantum computing milestone for biotech, a new way to get forever chemicals out of the water supply and more. You can sign up to get The Prototype in your inbox here . Florida Semiconductor Engine T he tech sector drives the U.S. economy, which in turn is undergirded by the semiconductor chips that power servers, computers, phones and more. Even though these chips are mostly designed domestically, they're not made in America: Nearly 90% are imported. That's an issue that Tawny Olore wants to help fix. She's the CEO of the Florida Semiconductor Engine, one of 10 regional networks backed by a two-yer, $15 million grant from the National Science Foundation. Half of that money is going towards research and development, for which it has five major projects. These include developing improved hardware security, designing 6G chips for the next generation of mobile internet and a project to build cryogenic, superconducting chips for AI and other forms of advanced computing. The other half of the spend is geared towards workforce development programs to ensure that there are people with the skills needed for the jobs the Engine hopes to bring back to the U.S. For example, it helped to develop an Associate's Degree for semiconductor engineering at Valencia College. The program, which is enrolling its first students this Fall, will train students to work in cleanrooms and operate the delicate equipment used to make chips. 'That's really important and shouldn't be diminished by the research and development projects that are so cool,' Olore said. 'You've got to have people there to be able to fill those jobs.' Stay tuned. IBM ran its simulation of mRNA structures on its Heron quantum processor. IBM L ast month, IBM rolled out its framework for building a 'fault-tolerant' quantum computer–one that can solve practical problems with low rates of error caused by the physics of its operations–by 2029. One major part of that is understanding what business problems exist that quantum computing can play a role in solving, Jamie Garcia, director of algorithms and partnerships at the company, told me. One potential: drug development. IBM has been working with biotech company Moderna since 2023, finding new techniques to predict the structures of messenger RNA (mRNA), which is at the core of Moderna's Covid vaccine and a number of other therapies it's developing. Figuring out how to use mRNA, which helps tell your body which proteins to make, is a complicated process. There are countless ways to code mRNA to make the same protein. For the Covid vaccine, for example, there are about 10^623 different possibilities. But the code is not enough–the order in which that code is arranged also affects how the final mRNA molecule is physically structured, which affects things like how durable it is and how large or small a dose might be–that's crucial for what arrangement will work best as a drug. 'That is sort of a combinatorial optimization issue that blows up really big, really fast,' Garcia said. For conventional computers, it would take centuries to solve them with brute force–even using AI models–because the hardware has to consider each possibility one at a time. That forces programmers to use shortcuts by simplifying the math to rougher approximations. A quantum computer, by contrast, can tackle portions of the problem in parallel–which makes for ultimately better calculations. Using quantum algorithms based on ones IBM had previously developed for financial problems, the two companies were able to successfully predict the structure of an mRNA sequence that was about 60 nucleotides long, which is at the upper limit of what a conventional computer can do. While that's much smaller than the sequences used for drugs, Garcia said that IBM's quantum computer will be able to predict bigger and bigger structures as the company builds out its capabilities. 'We're really excited about these results,' she said. 'And I think we're just going to keep finding the next generation of algorithms to really start checking the box when it comes to RNA problems.' DISCOVERY OF THE WEEK: NEW MATERIAL CLEANS FOREVER CHEMICALS FROM WATER Researchers at the University of Utah have invented a new material that can clean Perfluorooctanoic acid (PFOA) from water sources. PFOA belongs to the family of 'forever chemicals' that can contaminate soil and water without breaking down, and exposure to it can cause cancer. The new zirconium-based material not only attracts and absorbs PFOA, it also lights up when it does so, letting any engineers know that the forever chemical is present in a body of water. The cleaning material is also reusable–PFOA can be removed with conventional processes. This combination 'makes it a versatile and practical solution for water treatment and environmental monitoring,' lead author Rana Dalapati said in a statement. FINAL FRONTIER: SOUTH KOREA PLANS A MOON BASE In a public hearing earlier this week, South Korea's space agency laid out a roadmap for its exploration of space, The Korea Times reported. The agency is making its own plans to establish a permanent moon base by the year 2045. To help it get there, it will develop its own capabilities to launch and land humans on the lunar surface by 2040. WHAT ELSE I WROTE THIS WEEK In my other newsletter, InnovationRx, Amy Feldman and I looked at Sarepta's showdown with the FDA over its gene therapy for Duchenne Muscular Dystrophy, the FDA's new top drug regulator, a biotech company's strategy to fight cancer, a startup's therapy chatbot, and more. SCIENCE AND TECH TIDBITS Astronomers found an object in the outer solar system that seems to be moving in sync with Neptune. About 56 miles in diameter, it circles the Sun once for every ten times it takes the eighth planet. The orbits are in sync at this ratio despite being millions of miles apart, something that hasn't been seen before by scientists. Researchers at the University of California, Riverside have discovered a way to repair DNA that's been damaged by environmental stress, which could one day lead to prevention of afflictions like arthritis and inflammatory bowel disease. Around 10 million people live with HTLV-1 infection, which can lead to inflammatory diseases or even forms of cancer, but it currently has no treatments or vaccines. However, new research with mice suggests that existing HIV drugs could help prevent both transmission and disease. Street noise is one of the most annoying parts of city life, but Swiss scientists may have a solution: they've invented a mineral foam that can dampen street noise and is easier to install, since it's about four times thinner than conventional sound absorbers. PRO SCIENCE TIP: GET YOUR 7,000 STEPS A DAY It's long been a common rule of thumb to aim for 10,000 steps a day for optimal health, which can be a challenge for those who are stuck at their desks for work all day. But a new study suggests that you can get the same benefit with nearly one-third fewer steps. In a review of 57 different studies conducted in over ten countries, the researchers' analysis found walking around 7,000 steps a day reduced the risk of dementia and type two diabetes, and had other benefits as well. Which is not to say that getting 10,000 steps a day is bad–but 7,000 seems to represent an inflection point: the benefits accumulate quickly up to that point. Beyond it, the health benefits are more modest. WHAT'S ENTERTAINING ME THIS WEEK This month marks the 100th anniversary of the 'Scopes Monkey Trial'—in which schoolteacher John T. Scopes was found guilty of violating a Tennessee law that prohibited teaching the theory of evolution. So I kicked back and watched Inherit the Wind , Stanley Kramer's adaptation of the play of the same name, which is a fictionalized version of the Scopes trial. It's an absolutely mesmerizing courtroom drama that's still painfully relevant today, featuring a thunderous performance by Spencer Tracy as defense attorney Henry Drummond. It's streaming on Amazon Prime right now. MORE FROM FORBES Forbes South Park's Creators Are Now Billionaires By Matt Craig Forbes How Jeffrey Epstein Got So Rich By Giacomo Tognini Forbes Chicago's Kumiko Named World's Best Bar At 2025 Spirited Awards By Michael Solomon
